` ELTP (Elite Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

ELTP
vs
S&P 500

Over the past 12 months, ELTP has significantly outperformed S&P 500, delivering a return of +196% compared to the S&P 500's +13% growth.

Stocks Performance
ELTP vs S&P 500

Loading
ELTP
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ELTP vs S&P 500

Loading
ELTP
S&P 500
Difference
www.alphaspread.com

Performance By Year
ELTP vs S&P 500

Loading
ELTP
S&P 500
Add Stock

Competitors Performance
Elite Pharmaceuticals Inc vs Peers

S&P 500
ELTP
LLY
JNJ
NOVO B
ROG
Add Stock

Elite Pharmaceuticals Inc
Glance View

Market Cap
600.4m USD
Industry
Pharmaceuticals

Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. The company is headquartered in Northvale, New Jersey and currently employs 43 full-time employees. The company went IPO on 2014-02-20. The firm is principally engaged in the development and manufacture of oral, controlled-release products. The firm develops and manufactures generic products, products using controlled-release drug technology, products utilizing abuse deterrent technologies, and it develops and markets (either on its own or by license to other companies) generic controlled-release and abuse deterrent pharmaceutical products. Its segments include Abbreviated New Drug Applications (ANDA) for generic products and New Drug Applications (NDA) for branded products. Elite owns, licenses and contract manufactures products, including Phentermine HCl 37.5mg tablets , Phendimetrazine Tartrate 35mg tablets, Naltrexone HCl 50mg tablets, Isradipine 2.5mg and 5mg capsules, Oxycodone HCl Immediate Release 5mg, 10mg, 15mg, 20mg and 30mg tablets, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, among others.

ELTP Intrinsic Value
0.273 USD
Overvaluation 51%
Intrinsic Value
Price
Back to Top